/
/
Know Your Myeloma Immunotherapy: Antibody Drug Conjugates with Dr. Jesus Berdeja

Event Description

 Learn how antibody drug conjugates can help fight myeloma through the expertise of Dr. Jesus Berdeja. What is the mechanism of action? Which types of antibody drug conjugates are FDA approved? What is their side effect profile? What is the future of ADCs in myeloma? Learn more with us and come with your questions. 

Schedule & Agenda

01:00PM - 02:00PM
01:00PM
Audrey Burton-Bethkee
Introduction
Audrey introduces the agenda of the event and featured speaker Dr. Jesus Berdeja.
01:05PM
Dr. Jesus Berdeja
Presentation
Learn about how antibody drug conjugates can help fight myeloma and if you consider them in your myeloma treatment.
01:35PM
Audience
Questions and Answers
Type your questions in the chat and we will answer them!

Speakers & Moderators

The author Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the Myeloma Crowd as the Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

The author Dr. Jesus Berdeja
Dr. Jesus Berdeja

Jesus G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University. He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore. Prior to joining the staff at the Sarah Cannon Research Institute and Tennessee Oncology, Dr. Berdeja held appointments in the Stem Cell and Bone Marrow Transplant Program and the Division of Hematology and Oncology at Loma Linda University in Loma Linda, California. Dr. Berdeja has been certified a Diplomate in internal medicine, medical oncology, and hematology by the American Board of Internal Medicine. Additionally, he is an active member of several professional organizations, including the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, the International Myeloma Working Group, the Clinical Trials Myeloma Intergroup Committee, and the Center for International Blood and Marrow Transplant Research Plasma Cell Working Group. An active researcher, Dr. Berdeja has been the principal investigator on a number of funded clinical trials in the field of multiple myeloma. He has published extensively in the peer-reviewed literature and is a frequent invited lecturer.

Have Any Questions?

Thank you for your interest in the event. If you have any question we would love to help! Just send us a message below and we will get back to you as quickly as possible.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Sign up while there are spots left!

- May 24, 2022 / 01:00PM - 02:00PM EDT

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2021 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811